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Abstract
Background: Transforming growth factor type beta 1 (TGF-β1) produces skeletal muscle 
atrophy. Angiotensin-(1-7) (Ang-(1-7)), through the Mas receptor, prevents the skeletal muscle 
atrophy induced by sepsis, immobilization, or angiotensin II (Ang-II). However, the effect 
of Ang-(1-7) on muscle wasting induced by TGF-β1 is unknown. Aim: o evaluate whether T
Ang-(1-7)/Mas receptor axis could prevent the skeletal muscle atrophy induced by TGF-β1. 
Methods: This study assessed the atrophic effect of TGF-β1 in C2C12 myotubes and mice in 
absence or presence of Ang-(1-7), and the receptor participation using A779, an antagonist 
of the Mas receptor. The levels of myosin heavy chain (MHC), polyubiquitination, and MuRF-1 
were detected by western blot.  Myotube diameter was also evaluated. In vivo analysis included 
the muscle strength, fibre diameter, MHC and MuRF-1 levels by western blot, and ROS levels 
by DCF probe detection. Results: The results showed that Ang-(1-7) prevented the increase 
in MuRF-1 and polyubiquitined protein levels, the decrease of MHC levels, the myotubes/
fibre diameter diminution, and the increased production of reactive oxygen species (ROS) 
induced by TGF-β1. Utilizing A779 inhibited the anti-atrophic effect of Ang-(1-7). Conclusion: 
The preventive effect of Ang-(1-7) on skeletal muscle atrophy induced by TGF-β1 is produced 
through inhibition of ROS production and proteasomal degradation of MHC. 
Introduction Skeletal muscle atrophy is a pathological condition that affects skeletal muscle, producing loss of strength and muscle mass and leading to weakness [1, 2]. This condition can be produced by disuse, aging, bacterial infections, and chronic diseases [3-9]. There are 
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different soluble factors that can be involved in the development of muscle atrophy, among 
them transforming growth factor type beta 1 (TGF-β1) [10, 11]. TGF-β1 is a growth factor that regulates different processes in the cell such as proliferation, differentiation, regeneration, 
and apoptosis [12]. Studies indicate that the levels of TGF-β1 primarily increase in cases of chronic diseases such as cancer, heart failure, or diabetes [13-18], and this increase could cause skeletal muscle atrophy [19]. Our recent research elucidated the mechanism involved 
in the atrophic effect of TGF-β1 in skeletal muscle, which depends on an increase in reactive 
oxygen species (ROS) [11, 20]. We have shown the over-activation of ubiquitin-proteasome 
pathway (UPP), specifically an increase in the expression of E3 ubiquitin ligase MuRF-1. This 
occurs concomitant with a decrease in myosin heavy chain (MHC) protein levels and muscle 
fibre diameters. Another important regulator of skeletal muscle mass is the renin-angiotensin system 
(RAS) [21-24]. Previous antecedents had demonstrated that Ang-II - a vasoactive peptide of the classical RAS axis - induces skeletal muscle atrophy by an over-activation of UPP and myonuclear apoptosis [25-27]. The alternative arm of RAS or non-classical RAS, is formed by 
ACE-2 that induces the synthesis of Ang-(1-7) peptide that acts via Mas receptor producing 
contrary effects than classical RAS [24, 28]. In this context, our previous studies have shown 
that Ang-(1-7) prevents muscle atrophy induced by Ang-II, lipopolysaccharides, and disuse 
through the Mas receptor [29-32]. Based on this information, this study was designed to evaluate the effect of the Ang-(1-
7)/Mas receptor axis on the TGF-β1-dependent atrophic effect utilizing an in vitro and in vivo model of skeletal muscle atrophy. 
Materials and Methods
Animals studies 
Male C57BL/10J mice (12 weeks old) were used for the analysis. The mice were kept at room temperature on a 12:12 h light-dark cycle with access to food and water ad libitum [33]. Four groups of 
animals (with four mice per group) were randomly separated for the experiments: control, TGF-β1 (10 
ng) (Shenandoah Biotechnology Inc., PA, USA), Ang-(1-7) (100 ng/kg per min) (Sigma-Aldrich, MO, USA), 
and TGF-β1 plus Ang-(1-7). Independent experiments were performed in triplicate. Mice under ketamine/
xylazine anaesthesia were injected with TGF-β1 in the tibialis anterior (TA) muscle using the contralateral 
muscle as a control (injected with PBS) [34]. For the infusion of Ang-(1-7), two groups were implanted with 
osmotic micropumps (Alzet-Durect, CA, USA) 24 hours prior to TGF-β1 injection following manufacturer 
instructions [34]. The mice were killed under anaesthesia 72 h post-injection, and the TA muscles were 
dissected, removed, rapidly frozen with isopentane, and stored at -80 ºC until use. All protocols were 
conducted in strict accordance with and under the formal approval of the Animal Ethics Committee of the Universidad Andrés Bello.
Cell cultures 
The mouse skeletal muscle cell line C2C12 (American Type Culture Collection, VA, USA) were grown 
and used until passage 10. The cells were differentiated into myotubes for five days, as described previously 
[35-39]. The myotubes were pre-incubated for 30 min with Ang-(1-7) (10 nM) in presence or absence of 
Mas Inhibitor A779 (10 µM) (CPC Scientific, CA, USA) and then incubated with TGF-β1 (10 ng/ml) for the 
times indicated in each figure. 
Measurement of intracellular ROS levels 
The C2C12 myotubes were grown, differentiated, and treated on glass coverslips. After each treatment, 
the myotubes were washed with Hank's balanced salt solution (HBSS) and incubated with 10 μm of the cell-
permeant dye dichlorodihydrofluorescein (Invitrogen, CA, USA) for 30 min at 37 °C. Then, after duplicate 
washes with HBSS and one wash with phosphate-buffered saline (PBS), the myotubes were fixed with 4% 
paraformaldehyde for 10 min and washed with PBS. Nuclear staining was performed with 1 µg/ml Hoechst 
33258 in PBS for 10 min. After rinsing the cells were mounted with a fluorescent mounting medium (Dako 
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Corporation, CA, USA), viewed, and photographed with the Motic BA310 epifluorescence microscope (Motic, 
Hong Kong). 
Western blot analysis 
After each treatment, the protein extracts of myotubes were obtained by homogenizing the sample 
in radioimmunoprecipitation assay buffer, and the protein extracts of TA were obtained by homogenizing 
the muscle with TRIS/EDTA buffer, with a cocktail of protease inhibitors and 1 mM of phenylmethylsulfonyl 
fluoride in each case. Proteins were subjected to SDS-PAGE and transferred onto polyvinylidene difluoride 
membranes (EMD Millipore, Germany). The proteins were detected using the follow antibodies: mouse 
anti-MHC (1:3,000) (MF-20, University of Iowa Hybridoma Bank, IA, USA), rabbit anti-MuRF-1 (1:500) 
(ECM Biosciences, KY, USA), mouse anti-tubulin (1:5,000)(Santa Cruz Biotechnology, CA, USA). All 
immunoreactions were visualized by enhanced chemiluminescence (Thermo Fischer Scientific, MA, USA) 
using the FOTODYNE FOTO/Analyst Luminary Workstation Systems (FOTODYNE Inc., WI, USA). 
Contractile properties 
After treatment, the mice were anesthetized and the tibialis anterior (TA) muscles were removed 
and placed in a dish containing oxygenated Krebs-Ringer solution. Then the muscles were tied firmly with 
surgical silk, and transferred to a custom-built Plexiglas bath filled with oxygenated Krebs-Ringer solution 
thermostatically maintained at 37 C for optimal oxygen diffusion. The muscles were tied to a MLT 1030/D 
force transducer (AD Instruments, Dunedin New Zealand) and further were stimulated by supramaximal 
square wave pulses using a S48 Stimulator (Grass Research Instruments, RI, USA), controlled and measured 
using a Power Lab 4/35 (AD Instruments) and computed with Lab Chart analysis software (AD Instruments). 
Maximum isometric tetanic force was determined as previously reported, by calculating in addition, the 
specific net force (force normalized per total muscle fiber cross-sectional area, mN/mm2).
Indirect Immunofluorescence 
The C2C12 cells were grown, differentiated for five days, and treated on plastic coverslips. Then, each 
treated myotubes was washed twice in ice-cold HBSS, fixed in 4% paraformaldehyde, and permeabilized 
with 0.05% Triton X-100. Afterward, treatments were blocked for 1 h with a buffer containing 50 mM Tris-
HCl (pH of 7.7), 0.1 M NaCl, and 2% bovine serum albumin and incubated for 1 h with 1:100 mouse anti-
MHC in the same buffer. After antibody removal and several washes with HBSS, bound antibodies were 
detected by incubating the cells for 1 h with 1:500 affinity-purified Alexa Fluor dye-conjugated goat anti-
mouse antibody (Life Technologies, CA, USA). Nuclear staining was performed with 1 µg/ml Hoechst 33258 
in PBS for 10 min. After rinsing, the cells were mounted with a fluorescent mounting medium, viewed, and 
photographed with the Motic BA310 epifluorescence microscope. 
Wheat germ agglutinin staining 
Wheat germ agglutinin (WGA) staining labels glycoproteins at the sarcolemma [29, 31]. To stain the 
samples, freshly-frozen TA muscles were cryosectioned (8 µm) and placed on glass slides. The samples were 
fixed in 4% paraformaldehyde and incubated with Alexa-594-conjugated WGA (1:200) (Molecular Probes, 
OR, USA) and 1 µg/ml Hoechst 33258 in PBS. Triplicate PBS washes were performed between each step. 
After rinsing, the TA sections were mounted with a fluorescent mounting medium under glass coverslips, 
viewed, and photographed with the Motic BA310 epifluorescence microscope. 
Myotube/Fibre diameter determination and quantification 
Photographs obtained of immunofluorescent myotubes for MHC in different zones of the coverslip were used to obtain the myotube diameters. These measurements were determined through a blinded 
analysis with the ImageJ software (National Institutes of Health, MD, USA) of the images captured from 
each experimental condition. Myotube diameter was measured at three different points of the individual 
myotube, and then the values were averaged. Myotubes were defined as all multinucleated (containing three 
or more nuclei) cells positive for MHC stain. For the fibre diameter measurements, photographs obtained of 
TA sections stained with WGA were analysed from each experimental condition. The fibres were manually 
selected, and the minimal Feret’s diameter of each fibre was quantified by the ImageJ software. 
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Statistics 
Data were analysed statistically using one-way analysis of variance with a post-hoc Bonferroni 
multiple-comparison test (Sigma Stat Systat Software, CA, USA). Differences were considered statistically 
significant at P < 0.05.
Results
Ang-(1-7)/Mas receptor axis prevents the atrophic effects induced by TGF-β in C2C12 
myotubes by averting the decrease in myotube diameter and MHC levels
The effects of Ang-(1-7) on the atrophic effect of TGF-β1 on skeletal muscle were 
evaluated in C2C12 myotubes. First, myotube diameter was determined after pre-incubating 
myotubes with Ang-(1-7) for 30 min followed by a co-incubation with TGF-β1 for 72 h. 
Myotubes treated with TGF-β1 were qualitatively smaller than control myotubes, but in 
the presence of Ang-(1-7) shrinkage was prevented and myotubes were similar in size to 
the control (Fig. 1A). The effect of Ang-(1-7) incubation depended on the Mas receptor, as 
demonstrated by the inhibition of the Ang-(1-7)-dependent anti-trophic effect when the Mas 
receptor antagonist A779 was used (Fig. 1A). Quantification of myotube diameters showed 
that TGF-β1 treatment increased the proportion of myotubes with small diameters ([0-5 µm] 
and [5-10 µm]) and decreased the proportion with big diameters ([20-30 µm] and [30-40 
µm]) compared to the control (Fig. 1B). However, the myotubes treated with TGF-β1 in the 
presence of Ang-(1-7) showed a curve of myotube diameters similar to the control (Fig. 1B). 
Fig. 1. The Ang-(1-
7)/Mas receptor axis 
prevents TGF-β1-induced decrease in diameters of myo-
tubes (A) C2C12 myo-blasts differentiated 
for five days (myo-
tubes) were pre-in-cubated in absence or presence of Ang-
(1-7) (10 nM), A779 
(10 µM), or both for 
30 min, and then in-
cubated with TGF-β1 
(10 ng/mL) for 72 h. 
MHC was detected by indirect immuno-
fluorescence assay 
(green). Nuclei were 
labelled with Hoe-
chst staining (blue). The bar scale repre-
sents 100 μm. The myotube diameters 
from (A) were meas-
ured, quantified and plotted. The graphics 
shows the effect of Ang-(1-7) (B), and the effect of Ang-(1-7) plus A779 (c) on the distribution of myotube 
diameters in presence or absence of TGF-β1.  The values are expressed as a percentage of the total myotubes 
and correspond to the mean ± SD from three independent experiments (*, P < 0.05 vs control). 
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Interestingly, Ang-(1-7) alone slightly displaced the curve of myotube diameters towards 
the right, with a significant difference in the range of 30-40 µm (Fig. 1B). Co-incubation 
with A779, a Mas receptor antagonist, in the presence of Ang-(1-7) and TGF-β1 produced 
myotube diameters similar in size to those displayed in the presence of TGF-β1 (Fig. 1C).
The levels of myofibrillar proteins, such as MHC, were assessed in the presence or 
absence of TGF-β1, Ang-(1-7), and A779. The MHC levels decreased in the presence of TGF-β1 
treatment, displaying a 60% drop in comparison to the control (Fig. 2A). Co-incubation of 
cells with TGF-β1 and Ang-(1-7) displayed MHC levels similar to the control condition, while 
myotubes treated with Ang-(1-7), A779, and TGF-β1 displayed results similar to those of 
cells treated with TGF-β1 alone (Fig. 2A, B). These results indicate that the Ang-(1-7)/Mas 
receptor axis prevented the atrophic effect of TGF-β1 induced in C2C12 myotubes.
Ang-(1-7), through the Mas receptor, prevents the over-activation of ubiquitin proteasome 
pathway (UPP) induced by TGF-β1 in C2C12 myotubes
The UPP, the most studied catabolic pathway of sarcomere proteins such as MHC [40-
42], is over-activated in several types of skeletal muscle atrophy. Recently, TGF-β1 was found 
Fig. 2. Ang-(1-7) through the Mas receptor prevents 
TGF-β1-induced decrease of MHC levels in myotubes. 
C2C12 myotubes were incubated with TGF-β1 (10 ng/
mL) for 72 h in presence or absence of Ang-(1-7) (10 
nM), A779 (10 µM) (pre-incubated for 30 min), or 
both. (A) The MHC protein levels were determined 
by Western blot analysis. Tubulin was used as 
loading control. Molecular weights are shown in kDa. 
(B) Densitometric analysis for MHC protein levels 
with values normalized to tubulin and expressed as fold of induction relative to the control (myotubes 
without treatment). All values correspond to the 
mean ± SD from three independent experiments (*, 
P < 0.05 vs control without treatment; #, P < 0.05 vs 
TGF-β1 treatment).
Fig. 3. Ang-(1-7) through the Mas receptor averts 
the rise in MuRF-1 levels induced by TGF-β1 in C2C12 
myotubes. C2C12 cells differentiated for five days 
were incubated with TGF-β1 (10 ng/mL) for 48 h 
in presence or absence of Ang-(1-7) (10 nM), A779 
(10 µM) (pre-incubated for 30 min), or both. (A) The 
protein levels of MuRF-1 were determined by Western blot analysis. Tubulin was used as loading control. 
Molecular weights are shown in kDa. (B) The graph 
shows the quantitative analysis for MuRF-1 levels 
with values normalized to tubulin and expressed as fold of induction relative to the control (myotubes 
without treatment). All values correspond to the 
mean ± SD from three independent experiments (*, 
P < 0.05 vs control without treatment; #, P < 0.05 vs 
TGF-β1 treatment).
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to produce an increase in the E3 ubiquitin ligase MuRF-1 in myotubes. The effect of Ang-
(1-7)/Mas axis on TGF-β1-induced UPP over-activation was evaluated by determining the 
MuRF-1 levels and profile of the polyubiquitined protein. To accomplish this, myotubes were 
incubated in the presence or absence of Ang-(1-7), A779, and TGF-β1 for 48 h. Levels of 
MuRF-1 protein increased by 3.8-fold due to TGF-β1 incubation. In contrast, in the presence 
of Ang-(1-7) these levels decreased to amounts similar to the control, but co-incubation with 
A779 blocked the effect of Ang-(1-7) in the presence of TGF-β1, allowing for a 3.1-fold rise in 
MuRF-1 levels (Fig. 3A, B).
The effect of Ang-(1-7) on the polyubiquitined proteins was similar to that of MuRF-
1. Polyubiquitined proteins increased by 2.7-fold when incubated with TGF-β1, and the 
increase was prevented by Ang-(1-7). In the presence of A779, the preventive effect of Ang-
(1-7) was impeded, and the levels of polyubiquitination were similar to those in samples 
with only TGF-β1 (Fig. 4A, B). 
Together, these results indicate that Ang-(1-7)/Mas axis prevented the over-activation 
of UPP induced by TGF-β1 in C2C12 myotubes, specifically, the increase in MuRF-1 expression 
and polyubiquitined proteins. 
TGF-β1-dependent ROS production is prevented by Ang-(1-7)/Mas receptor axis in C2C12 
myotubes Previously, we have demonstrated that ROS production is a key regulator in the skeletal 
muscle atrophy induced by TGF-β1. To evaluate the effect of Ang-(1-7) on ROS induced by 
TGF-β1, myotubes were co-incubated with TGF-β1, Ang-(1-7), and A779, and the ROS levels 
were measured using the fluorescent dye CM-DCF (Fig. 5A). The DCF-positive myotubes were 
Fig. 4. The Ang-(1-7)/Mas receptor axis prevents an 
increase in the polyubiquitination of protein induced 
by TGF-β1 in myotubes. C2C12 cells differentiated for 
five days (myotubes) were pre-incubated in absence 
or presence of Ang-(1-7) (10 nM), A779 (10 µM), or 
both and then incubated with TGF-β1 (10 ng/mL) for 
48 h as indicate by the figure. (A) The polyubiquitined 
protein levels were determined by Western blot 
analysis using tubulin as loading control. Molecular 
weights are shown in kDa. (B) Densitometric 
analysis for polyubiquitined proteins levels with 
values normalized to tubulin and expressed as fold of induction relative to the control (myotubes 
without treatment). The values correspond to the 
mean ± SD from three independent experiments (*, 
P < 0.05 vs control without treatment; #, P < 0.05 vs 
TGF-β1 treatment).
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quantified for each condition. TGF-β1-dependent ROS production (2.8-fold of induction 
relative to control) was partially decreased due to the effect of Ang-(1-7) (1.65-fold relative 
to control). The use of A779 hindered the effect of Ang-(1-7), and the ROS levels were similar 
to those of TGF-β1 alone (Fig. 5B). 
These results indicate that Ang-(1-7) through Mas receptor decreased the ROS 
production induced by TGF-β1 in C2C12 myotubes.
Ang-(1-7) prevented the atrophic effect of TGF-β1, specifically muscle strength, fibre 
diameter and myosin level diminution in the tibialis anterior muscle of mice.
We evaluated the effect of Ang-(1-7) on the decline in the muscle strength induced by TGF-β. The measures of isometric force showed that Ang-(1-7) is able to recover the decline in muscle strength produced by TGF-β (Fig. 6A). In a previous report, we showed that TGF-β1 
injected into TA muscle produces a diminution in the diameter of the fibres and decreases 
the MHC protein levels [11]. To test the anti-atrophic effect of Ang-(1-7) in this model, the 
peptide was systemically administered to mice that were then injected with TGF-β1 in the TA. 
The results indicated that diminution in muscle fibre size induced by TGF-β1 was prevented 
when Ang-(1-7) was administered (Fig. 6B). The TGF-β1 injections produced a shift towards 
fibre of a lesser diameter than the control condition, while in the presence of Ang-(1-7) this 
effect was lost and fibre diameters were similar to the control condition (Fig. 6C). When the 
MHC levels were evaluated, Ang-(1-7)-treated samples did not display the decrease in MHC 
levels induced by TGF-β1 (Fig. 6D, E).
These results show that the anti-atrophic effects of Ang-(1-7) were observable in an in 
vivo model of TGF-β1-induced muscle wasting in mice.
Fig. 5. The increase of reactive oxygen 
species (ROS) induced by TGF-β1 is 
prevented by Ang-(1-7) through the 
Mas receptor in myotubes. (A) C2C12 
myotubes were incubated with TGF-β1 
(10 ng/mL) for 24 h in presence or 
absence of Ang-(1-7) (10 nM), A779 
(10 µM) (pre-incubated for 30 min), or both. The ROS levels were then determined by loading the cells with a 
CM-DCF-DA probe, and the nuclei were 
labelled with Hoechst. Fluorescence was determined by microscopy. Scale 
bar represents 100 µm. (B) The graph 
shows the quantification of DCF-positive myotubes for the different treatments. The values are expressed as fold of induction relative to the myotubes without treatment and 
correspond to the mean ± SD from 
three independent experiments (*, P < 
0.05 vs control without treatment; #, P 
< 0.05 vs TGF-β1 treatment).
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Discussion 
The present study demonstrates that Ang-(1-7)/Mas receptor axis averted the atrophic 
effects induced by TGF-β1 in C2C12 myotubes. The results show that the use of Ang-(1-7) 
prevented an increase in ROS levels and the over-activation of UPP, specifically the increased 
MuRF-1 protein levels and polyubiquitined proteins. Concomitantly, Ang-(1-7) prevented 
the decrease in MHC protein levels and myotube and fibre diameters in skeletal muscle.
Despite that this study has several limitations, mainly by the in vitro experiments 
and the mechanisms that were derived from them, our findings must be corroborated in a pathological status in which an increase of TGF−β can be observed. 
The beneficial effects of Ang-(1-7) have been described in different tissues and cell 
types [43-48]. In skeletal muscle, previous research performed on rodent muscle wasting 
Fig. 6. Ang-(1-7) prevents 
the decrease of the fibre 
diameters and MHC levels 
induced by TGF-β1 in the 
tibialis anterior (TA) of mice. 
(A) TA muscles of male C57/
BL10 mice were injected with 
either PBS (control) or TGF-β1 
(10 ng) at day 1 and 3. To the correspondent group, osmotic 
micropumps with Ang-(1-7) 
(100 ng/kg per min) or vehicle 
were implanted 24 h prior to 
first injection with TGF-β1. 
After 5 days of the first TGF-β 
injection, muscles were excised and maximal isometric strength 
(mN/mm2) was evaluated. 
Values represent the mean ± 
SD of triplicate independent experiments and are expressed as percentage of the net force relative to mice treated with 
vehicle and injected with 
PBS. In each experiment, three mice were used for each 
experimental condition (*, P < 
0.05 vs control vehicle; #, P < 
0.05 vs TGF-β1 vehicle). (B) TA 
muscles of male C57/BL10 mice were injected with either PBS (control) or TGF-β1 (10 ng) for once. To the 
correspondent group, osmotic micropumps with Ang-(1-7) (100 ng/kg per min) or vehicle were implanted 
24 h prior to the injection with TGF-β1. After 72 h, the muscles were removed. Cryosections of TA muscles 
were stained with WGA and the fibre Feret's diameter was determined. The bar scale corresponds to 100 μm. 
Quantitative analysis for the fibre diameters is shown in (C). Values are expressed as the percentage of the 
total fibres quantified and correspond to the mean ± SD from three independent experiments (*, P < 0.05). 
The MHC protein levels were determined by Western blot analysis. Tubulin was used as loading control. 
Molecular weights are shown in kDa (D). The quantitative analyses for MHC levels are shown (E). The values 
were normalized to tubulin and are expressed as fold of induction relative to the control incubated without 
TGF-β1. Values correspond to the mean ± SD from three independent experiments (*, P < 0.05 vs control 
vehicle; #, P < 0.05 vs TGF-β1 vehicle). 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
id
ad
 A
nd
re
s 
Be
llo
 - 
UN
AB
   
   
   
   
   
   
   
   
20
0.
27
.7
2.
25
1 
- 4
/2
8/
20
17
 1
0:
15
:3
6 
PM
Cell Physiol Biochem 2016;40:27-38
DOI: 10.1159/000452522 
Published online: November 14, 2016 35
Ábrigo et al.: Angiotensin (1-7) Prevents Muscle Wasting Induced by TGF-b
Cellular Physiology 
and Biochemistry
© 2016 The Author(s). Published by S. Karger AG, Basel
www.karger.com/cpb
induced by disuse [32], lipopolysaccharides [31], and Ang-II [29, 30], indicates that Ang-(1-
7) prevents muscle atrophy through the Mas receptor. This study is the first to demonstrate 
the protective effect of Ang-(1-7) in muscle atrophy induced by TGF-β1.Our previous study establishes that one of the primary mechanisms involved in the 
development of skeletal muscle atrophy induced by TGF-β1 is the increase in ROS production 
[11]. This study demonstrated that Ang-(1-7)/Mas axis prevented the rise of ROS levels 
induced by TGF-β1 in C2C12 myotubes. These results concur with previous evidence indicating 
that Ang-(1-7) via the Mas receptor decreases oxidative stress in different cell types, such as 
adipocytes [49], cerebral endothelial cells [50], and, interestingly, in pathologies associated with skeletal muscle atrophy such as diabetes [51], cardiac failure [52], and hepatic damage 
[53]. Additionally, previously published results by us shows that Ang-(1-7)/Mas receptor 
prevents ROS induction by Ang-II in skeletal muscle cells [54]. Therefore, Ang-(1-7) could 
have an antioxidant effect in skeletal muscle atrophy conditions induced by TGF-β1. 
Among the main sources of intracellular ROS is NADPH oxidase (NOX) [55, 56]. Previous 
work indicates that the TGF-β1-induced rise in ROS production is dependent on NOX in 
skeletal muscle cells [20]. Other groups demonstrate that Ang-(1-7) decreases mRNA levels 
of NOX in adipocytes [49] or the NOX activation [57, 58]. Based on this research, Ang-(1-7) 
could block the NOX-dependent ROS production. Further investigation is necessary in order 
to study this possible Ang-(1-7) effect.
An increase in TGF-β1 levels as well as in its signalling is observed in various skeletal 
muscle disorders [19, 59-61]. One of these is Duchenne muscular dystrophy, in which mdx 
mice has serve as murine models [62]. Interestingly, the muscle wasting associated with mdx 
mice is decreased by an Ang-(1-7) infusion that inhibits TGF-β1 signalling; thus, reducing 
fibrosis and restoring muscle strength [34]. TGF-β1 signaling also increases during muscle 
atrophy induced by Ang-II or disuse [63-66]. In these muscle wasting models, Ang-(1-7) displays an anti-atrophic effect evidenced by the prevention of decreases in muscle strength, 
UPP over-activation, and decreases in MHC levels [32, 54]. However, other complementary 
studies must be performed to evaluate the direct relation between the Ang-(1-7) mediated 
inhibition of TGF-β1 signalling and the anti-atrophic effect in these models.
One of the possible mechanisms regulated by Ang-(1-7) is the signalling pathway 
activated by TGF-β1. The canonical TGF-β1 pathway is mediated by the phosphorylation of 
Smad2/3 proteins [67] and further transcription of target genes. In this pathway, Smad7 
is an inhibitory protein, acting through negative feedback by blocking the Smad2/3 
phosphorylation [67]. In dystrophic mdx mice, previous research demonstrated that Ang-(1-
7) increases Smad7 expression [34]. This study, we have demonstrated that TGF-β1 induces the phosphorylation of both Smad proteins and that this pathway is involved in the atrophic 
effect induced by TGF-β1 (unpublished result) in C2C12 myotubes. However, further studies are necessary to evaluate the possible participation of Smad7 on the anti-atrophic effect 
mediated by Ang-(1-7). 
The present study shows that Ang-(1-7), through the Mas receptor, prevented the 
atrophic effects induced by TGF-β1 in skeletal muscle cells and tissue. In this context, the 
clinical importance of our results is that could be extrapolated to diseases in which TGF-β 
levels are increased (such as Duchenne muscular dystrophy) and evaluate the effect on 
muscle atrophy. Thus, Ang-(1-7) could be used as a therapeutic alternative for the treatment of skeletal muscle atrophy induced by different chronic diseases 
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